In order for our site to display correctly you will need a newer version of your web browser.

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Diseases

Leukemias / Lymphomas : High risk Hodgkin lymphoma

Description

Hodgkin lymphoma is a cancer of the lymph system (a part of the body’s immune system). The lymph system is made up of tissue throughout the body that makes and stores infection-fighting cells. The term “risk” refers to the chance of the cancer coming back after treatment.

In this study, a commonly used multi-drug chemotherapy (anti-cancer) regimen for Hodgkin lymphoma will be used called “OEPA/COPDac”, except that a new drug called “brentuximab vedotin (also called Adcetris®)” will be substituted for one of the usual drugs called vincristine, making this treatment “AEPA/CAPDac”. Brentuximab vedotin is a drug known as an “antibody-drug conjugate (ADC)”. It is made up of 2 parts. The first part is a type of antibody (a man-made version of an immune system protein) that finds and attaches to the surface of most lymphoma cells. The second part is a chemotherapy (anti-cancer) drug that stops the cancer cell from dividing, and kills the cancer cell.

This study has 2 parts:

1. Treatment phase: treatment with chemotherapy and in some participants, radiation therapy. Radiation will start within 2-3 weeks after completing all CAPDac chemotherapy and blood counts have recovered. Radiation treatments will be given to lymph node groups that did not go into remission after the first 2 cycles of AEPA chemotherapy.

2. Follow-up phase: monitor you long-term to look for signs Hodgkin lymphoma has returned and for late effects of treatment

Objectives

Find out how many participants’ cancer will go into complete remission (no signs or symptoms of Hodgkin lymphoma) after the first 2 cycles of chemotherapy (AEPA).

Find out how many participants will go into long-term remission after being treated on this study.

Learn more about the safety of this treatment and the side effects.

Find out if the for those participants that suffer a relapse, location in the body where the Hodgkin lymphoma relapses is realted to the volume of radiation.Find out how the body uses and gets rid of brentuximab vedotin (pharmacokinetics).

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.